1. INTRODUCTION
SARS-CoV-2 causing COVID-19 has affected millions worldwide till date. Although initially described for its respiratory symptoms and complications, new research has highlighted the virus’s wide-ranging effects, which go well beyond the respiratory system. The cardiovascular system has drawn much attention because of the various cardiac manifestations, calling for more research and comprehension
The development of new-onset atrial fibrillation (NOAF) in COVID-19 is one such cardiac manifestation. Several underlying cardiovascular and systemic conditions have been linked to atrial fibrillation. However, the intriguing link between COVID-19 and AF has created a particular focus in cardiovascular medicine, providing additional information about the underlying mechanisms, clinical implications, and potential therapeutic options. Although there are variations in the prevalence of NOAF in COVID-19 as documented by prior studies, it is clear that it can affect how the disease manifests clinically.,
The presence of NOAF in COVID-19 raises significant clinical and public health issues, related to the effect of NOAF in COVID-19 outcomes, such as mortality, hospitalization rates, and the course of the disease. Hence, we present a systematic review and meta-analysis to compile and analyze the current literature on NOAF in COVID-19. By combining data from various studies, we aim to provide a more comprehensive understanding of the prevalence, clinical importance, and potential underlying mechanisms of NOAF in COVID-19.